William M. Duck*, Jeremy Sobel*, Janet M. Pruckler*, Qunsheng Song*, David Swerdlow*, Cindy Friedman*, Alana Sulka*, Balasubra Swaminathan*, Tom Taylor*, Mike Hoekstra*, Patricia M. Griffin*, Duane Smoot†, Rick Peek‡, DavidC. Metz§, Peter B. Bloom¶, Steven Goldschmid¶, Julie Parsonnet#, George Triadafilopoulos#, Guillermo I. Perez-Perez**, Nimish Vakil††, Peter Ernst‡‡, Steve Czinn§§, Donald Dunne§§, and Ben D. Gold*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Howard University Medical Center, Washington, DC, USA; ‡Vanderbilt University Medical Center, Nashville, Tennessee, USA; §University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA; ¶Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA; #Stanford University Medical Center, Palo Alto, California, USA; **New York University School of Medicine, New York, New York, USA; ††Sinai Samaritan Medical Center, Milwaukee, Wisconsin, USA; ‡‡University of Virginia, Charlottesville, Virginia, USA; §§University Hospitals of Cleveland, Cleveland, Ohio, USA; ¶¶Indiana University Medical Center, Indianapolis, Indiana, USA
Main Article
Table 5
Phase I multivariate analysis of risk factors for resistance to >1 antimicrobial agent among H. pylori isolates submitted to HARP, 1998–2002a
| Exposure |
Odds ratio (95% CI) |
Patient treated another time for infection
|
6.0 (2.0–20)
|
Took Mylanta in last 12 mo
|
0.3 (0.1–0.8)
|
HARP site
|
|
New York, NY
|
0.2 (0.1–0.7)
|
Palo Alto, CA
|
0.2 (0.1–0.7)
|
Atlanta, GA
|
0.2 (0.1–0.6)
|
| Nashville, TN |
0.4 (0.2–0.9) |
Main Article
Top of Page